Nancy Thornberry - 02 Sep 2026 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Reporting relationship: Director
Issuer ticker: DNLI
Reported as of: 02 Sep 2026
Net transaction value: -$261,928
SEC form: 4
Accepted by SEC: 04 Sep 2026, 17:02:24 UTC
Prior SEC filing: 23 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Tyler Nielsen, by power of attorney

Key filing fact

Nancy Thornberry filed Form 4 for Denali Therapeutics Inc. (DNLI) on 04 Sep 2026.

Key facts

This page summarizes Nancy Thornberry's Form 4 filing for Denali Therapeutics Inc. (DNLI).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 04 Sep 2026, 17:02.

Change

Previous filing in this sequence was filed on 23 Jun 2026.
Current net transaction value: -$261,928.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001797826 Primary reporting owner

Thornberry Nancy

Relationship: Director
Address: C/O DENALI THERAPEUTICS INC., 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Signature: /s/ Tyler Nielsen, by power of attorney
Signature date: 04 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DNLI transaction

Common Stock

Sale

Transaction value: $247,328
Shares: -10,824
Change %: -35%
Price: $22.85
Shares after: 20,301
Date: 02 Sep 2026
Ownership: Direct
Footnotes: F1, F2, F3

DNLI transaction

Common Stock

Sale

Transaction value: $14,600
Shares: -615
Change %: -3%
Price: $23.74
Shares after: 19,686
Date: 02 Sep 2026
Ownership: Direct
Footnotes: F1, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted June 3, 2026.

Footnote F2

The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $22.54 to $23.52 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Footnote F3

Includes 6,408 Unvested RSUs.

Footnote F4

The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $23.59 to $23.85 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.